[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Colorado, Boulder\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":429},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,42,63,91,114,140,162,190,211,229,252,280,301,324,351,383,408],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100552306","pathophysiology-of-circadian-rhythm-delayed-sleep-wake-phase-disorder-100552306",false,"NCT06471374","Pathophysiology of Circadian Rhythm Delayed Sleep Wake Phase Disorder","Inclusion Criteria:\n\n* Delayed sleep wake phase disorder diagnosis\n* Altitude history: currently residing at Denver altitude or higher\n* BMI normal to moderately overweight\n\nExclusion Criteria:\n\n* Recent medical condition\n* Psychiatric disorder\n* Sleep disorder\n* Medication use",true,"ALL","16 Years","40 Years",{"count":20,"type":21},66,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to understand factors that contribute to delayed sleep wake phase disorder (DSWPD). The investigators will examine whether patients with DSWPD exhibit alterations in circadian rhythms and sensitivity to light compared to healthy controls. The investigators will also test a new method of predicting circadian rhythms form a blood sample.",[27,28],"Delayed Sleep Phase Syndrome","Delayed Sleep Phase","RECRUITING","2026-06-15",{"date":32,"type":33},"2026-06-17","ACTUAL",{"date":35,"type":33},"2024-04-02",{"date":37,"type":21},"2028-07",{"name":39,"class":40},"University of Colorado, Boulder","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":15,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},"100538898","biomarkers-for-peripheral-circadian-clocks-in-humans-100538898","NCT06296823","Biomarkers for Peripheral Circadian Clocks in Humans","Inclusion Criteria:\n\n1\\) 17-35 years old 2) English speaking 3) Healthy 5) Altitude history: Currently residing at Denver altitude or higher\n\nExclusion Criteria:\n\n1\\. Any medical, psychiatric, or sleep disorder.","17 Years","35 Years",{"count":51,"type":21},14,[24],"The purpose of this project is to improve our understanding of peripheral circadian rhythms in humans. Circadian clocks are present in most tissues of the body with importance for optimal physiological function, health, and behavior. This project will utilize simulated jetlag protocols to systematically test novel hypotheses about the regulation of peripheral circadian rhythms in humans. Specifically, we will examine how changes in the time of when we are exposed to light and the timing of when we eat impacts proteins in the blood and saliva that represent rhythms from clocks in the brain (e.g., rhythms of the hormones melatonin and cortisol coordinated by the brain) and rhythms from clocks in body tissues (e.g., proteins made by immune and bone cells, and cells in the stomach and liver). We also aim to discover new blood-based biomarkers of peripheral rhythms in humans. We anticipate our findings will be the first step in developing novel circadian based treatments for aligning peripheral clocks under conditions such as jetlag, and for developing novel circadian biomarkers that will advance our scientific understanding of circadian rhythms.",[55],"Circadian Rhythms",{"date":32,"type":33},{"date":58,"type":33},"2023-09-01",{"date":60,"type":21},"2027-08-31",{"name":39,"class":40},1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":71,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":62},"100524310","phase-2-longitudinal-outpatient-treatment-for-cannabis-use-disorder-100524310","NCT06107062","Longitudinal Outpatient Treatment for Cannabis Use Disorder","Hemp-derived Cannabidiol for the Treatment of Cannabis Use Disorder: A Double-blind Placebo-controlled Randomized Trial","LOTUS","Inclusion Criteria:\n\n* Regular use (at least 4 times per week) of cannabis concentrates for at least the last year.\n* Meets DSM5 criteria for at least moderate CUD.\n* Currently seeking to cut down or stop cannabis use.\n\nExclusion Criteria:\n\n* Use of any substance of abuse besides alcohol, nicotine, or cannabis (e.g., cocaine, non-prescription use of opiates, methamphetamine, MDMA, benzodiazepines, or barbiturates) in the past 90 days, as indicated by self-report and urine toxicology screening (Syva Rapid Test) at baseline.\n* Use of CBD-dominant products in the past 90 days, as evidenced by self-report of use of a CBD\\>THC product or CBD blood levels at baseline of \\>= 5 ng\u002FmL\n* Alcohol use on 3 or more days per week, and\u002For \\> 3 drinks per drinking day in the past 90 days. Participants must also have a breath alcohol level of 0 at the beginning of each study visit.\n* Daily nicotine use.\n* Meets DSM-5 diagnostic criteria for a psychotic disorder (e.g., schizophrenia, schizophreniform disorder, schizoaffective disorder), bipolar disorder, or major depression with suicidal ideation, or has a history of treatment for these disorders. Psychiatric disorders will be assessed with the Mini-International Neuropsychiatric Interview (MINI).\n* Current cardiovascular or respiratory disease (e.g., coronary artery disease, severe asthma, chronic obstructive pulmonary disease, etc.)\n* Current use of psychotropics (e.g., antidepressants, anxiogenics), which may dampen effects of CBD.\n* Current use of anti-epileptic medications (e.g., clobazam, sodium valproate) or medications known to have major interactions with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, and\u002For teriflunomide).\n* Current or past hepatocellular disease, as indicated by alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2 times the upper limit of the normal range at screening or a history of liver disease irrespective of AST and ALT at the time of screening.\n* For participants assigned female at birth, pregnancy or trying to become pregnant as indicated by a urine pregnancy test administered at the beginning of each study visit.\n* History of seizures\n* Current use of potent CYP2C19 or CYP3A4 inducers (e.g., Rifampin, apalutamide, carbamazepine, enzalutamide, ivosidenib9, lumacaftor, ivacaftor, phenytoin, St. John's wort, Fosphenytoin, Mitotane, Phenobarbital, Primidone), or strong CYP3A inhibitors (e.g., clarithromycin, HIV protease inhibitors, and most antifungals), 2C19 inhibitors (e.g., fluoxetine, Lansoprazole, Tricyclic antidepressants (TCAs))\n* Allergy to study medications (hemp seed oil, hemp extract, gelatin, glycerin)","21 Years",{"count":73,"type":21},165,[75],"PHASE2","This study is a placebo-controlled randomized trial comparing the effects of hemp-derived cannabidiol (CBD) with and without Delta-9-tetrahydrocannabinol (THC), relative to placebo, on reducing cannabis use and cannabis use disorder (CUD) symptoms in adult treatment seeking cannabis concentrate users with CUD. Participants enroll in the study for 8 weeks (with telehealth follow-ups at 12 and 16 weeks) and are randomized to either full spectrum CBD, broad spectrum CBD, or placebo. Participants are also engaged in five weeks of psychotherapy treatment for CUD. Blood is collected to quantify investigational drug exposure and cannabis use. Participants also complete self-report measures of medical history, sleep quality, subjective cognitive function, physical activity, psychological functioning, substance use, and acute drug effects.",[78],"Cannabis Use Disorder",[78,80,81,82],"CUD","Cannabidiol","CBD","2026-06-10",{"date":85,"type":33},"2026-06-12",{"date":87,"type":33},"2024-07-26",{"date":89,"type":21},"2029-03-31",{"name":39,"class":40},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":71,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100633488","phase-2-mechanisms-of-cannabidiol-and-sleep-in-the-context-of-alcohol-use-100633488","NCT07527338","Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use","CALM","Inclusion Criteria:\n\n* Able to provide informed consent\n* Self reported poor sleep quality (PSQI score \\>5)\n* Hazardous or harmful levels of alcohol consumption (MINI AUD score ≧2)\n* No current moderate or severe alcohol withdrawal symptoms (CIWA-Ar)\n* For female participants of childbearing potential: Not pregnant or lactating at the time of study enrollment or trying to become pregnant as confirmed by urine preg. Lack of childbearing potential confirmed by a history of amenorrhea for at least 12 consecutive months and serum FSH level within the laboratory's reference range for postmenopausal females OR documented bilateral oophorectomy and\u002For hysterectomy\n* For female participants of childbearing potential: Agree to use a highly effective contraception method (i.e., a method with a failure rate of less than 1 percent per year when used consistently and correctly) starting at least five days before you begin the study and continuing for full participation.\n* No current use of sleep medications including CBD in the last 90 days\n* No history of complicated alcohol withdrawal (i.e., seizure, delirium tremens, or alcohol hallucinosis).\n* No current or past 6 months active suicidal ideation or suicidal behavior\n* No current diagnosis, or family history of diagnosis, of psychosis; current major psychiatric illness, such as bipolar disorder, major depression, or schizophrenia\n* No current cannabis use disorder (MINI SUD for cannabis score ≧2)\n* History of previous exposure to guaiol through CBD or other cannabis product\n\nExclusion Criteria:\n\n* Current use of anti-epileptic medications (e.g., clobazam, sodium valproate, lamotrigine)\n* Greater than low risk for obstructive sleep apnea (STOP-BANG \\\u003C=4 or Moderate or greater risk as calculated by Nox Noxturnal Software from baseline PSG data)\n* Current use of medications known to have major interactions with Epidiolex (e.g., brexanolone, buprenorphine, colchicine, esketamine, fezolinetant, ketamine, leflunomide, levoketoconazole, levomethadyl acetate, lomitapide, mipomersen, morphine, pexidartinib, pralsetinib, propoxyphene, relugolix, sodium oxybate, teriflunomide, and venetoclax)\n* Current use of anti-psychotic medications\n* Current use of potent CYP2C19 or CYP3A4 inducers (e.g., Rifampin, apalutamide, carbamazepine, enzalutamide, ivosidenib9, lumacaftor, ivacaftor, phenytoin, St. John's wort, Fosphenytoin, Mitotane, Phenobarbital, Primidone)\n* History of hypersensitivity reactions to cannabidiol\n* Liver function test (Alanine transaminase \\[ALT\\] and Aspartate transaminase \\[AST\\]) levels ≥2x the upper normal limits at baseline\n* Moderate or severe liver disease\n* Allergy or aversion to gelatin (softgels contain porcine gelatin)\n* Report of illegal drug use (e.g., cocaine, methamphetamine) in the past 90 days or positive screening on urine toxicology test at Baseline visit.\n* Uncontrolled hypertension\n* Blood pressure findings concerning for moderate or severe alcohol withdrawal at baseline\n* Abnormal resting heart rate, defined as \\\u003C60 bpm or \\>100 bpm at baseline",{"count":99,"type":21},58,[75],"The goal of this clinical trial is to learn if cannabidiol helps to improve sleep and decrease alcohol use. It will also learn about the safety of cannabidiol. The main questions it aims to answer are:\n\nDoes 4 weeks of nightly cannabdiol use:\n\n1. improve sleep quality and time spent in REM sleep?\n2. decrease alcohol use and alcohol craving?\n3. pose any safety risks?\n\nResearchers will compare cannabidiol to a placebo (a look-alike substance that contains no drug).\n\nParticipants will:\n\nTake cannabidiol every night for 4 weeks Visit the clinic once at the beginning and once at the end of the study Wear an activity monitoring watch while in the study Complete an at-home sleep test both at the beginning and the end of the study Check in once a week with researchers via video conference",[103,104],"Sleep","Alcohol Misuse","NOT_YET_RECRUITING","2026-06-09",{"date":108,"type":33},"2026-06-11",{"date":110,"type":21},"2026-07-01",{"date":112,"type":21},"2031-04-01",{"name":39,"class":40},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":15,"sex":16,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":41},"100602780","exercise-adherence-and-cognitive-decline-phase-2-100602780","NCT07127965","Exercise Adherence and Cognitive Decline: Phase 2","Exercise Adherence and Cognitive Decline: A Goal-setting and Exercise Intensity Intervention Collaboratively Developed With the Black Community","MOVE","Inclusion Criteria:\n\n* \\\u003C3 incorrect responses on the Pfeiffer Mental Status Questionnaire\n* Ages 45 to 65\n* Consent to be randomized to conditions\n* Planning to remain in the Denver metro area for the next 14 months\n* Identify as Black or African American\n\nExclusion Criteria:\n\n* Currently physically active (i.e., \\>90 min\u002Fweek of moderate PA or \\>40 min\u002Fweek of vigorous PA consistently for the past 6 months)\n* On antipsychotic medications or currently under treatment for any serious psychiatric disorder including Alzheimer's or dementia\n* Inability to walk 3 blocks without chest pain, shortness of breath, or lightheadedness\n* Inability to climb 2 flights of stairs without chest pain, shortness of breath, or lightheadedness\n\nPCP Exclusion Criteria:\n\n* Answers \"yes\" to 1 or more of the 7 general questions of the PAR-Q+ and answers yes to any of the follow up questions.\n* Blood pressure at baseline is greater than 160\u002F100\n* Blood pressure at baseline is between 140\u002F90 - 160\u002F100 and the participant is currently taking blood pressure medication\n* Blood pressure \\> 210\u002F90 mmHg (for men) or \\> 190\u002F90 mmHg (for women) immediately after exercise","45 Years","65 Years",{"count":125,"type":21},226,[24],"The purpose of this study is to conduct a test of a goals-based program to help people exercise more. This program was designed for individuals aged 45-65 from the Black community. Low levels of physical activity are related to health problems such as heart disease, diabetes, and cognitive decline. People of color are more negatively impacted by these conditions and have also historically been underrepresented by research seeking to increase physical activity. The investigators have developed this goals-based exercise promotion program with the help of a Black-led community-based organization (The Gyedi Project) and a Community Advisory Board made up of stakeholders in the Black community.",[129],"Cognitive Decline",[131,132,133,129],"Goals","Goal Difficulty","Exercise Intensity",{"date":108,"type":33},{"date":136,"type":33},"2025-11-05",{"date":138,"type":21},"2028-08-31",{"name":39,"class":40},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":148,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":161,"locationsCount":62},"100538379","phase-2-cannabidiol-and-older-adult-cannabis-users-100538379","NCT06290063","Cannabidiol and Older Adult Cannabis Users","Rocky Mountain Cannabis Research Center - Cannabidiol and Older Adult Cannabis Users: A Randomized, Placebo-Controlled Study","QUARTz","Inclusion Criteria:\n\n* At least 60 years of age\n* Able to provide informed consent\n* Must have used a cannabis product at least once with no negative effects\n* Must not have been regularly using any cannabis products (\\\u003C3x\u002Fmonth) in the last 6 months\n* Female participants must be postmenopausal\n* Liver function tests (Alanine transaminase (ALT) and\n* Aspartate transaminase (AST)) must show levels no greater than 2x the upper normal limits for age\n* Must be currently taking medication\u002Fs for pain, sleep, and\u002For mood\n\nExclusion Criteria:\n\n* Blood alcohol level \\> 0 at screening (to sign consent form)\n* Report of other drug use (cocaine, opiates, methamphetamine) in the past 90 days or fail urine screen for any of these drugs\n* Past or current diagnosis, or family history of diagnosis of psychosis\n* Current use of anti-epileptic medications (e.g. clobazam, sodium valproate)\n* Current use of medications known to have major interactions with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, and\u002For teriflunomide).\n* Current use of antipsychotic medications\n* Currently undergoing chemotherapy (to prevent drug interactions)","60 Years",{"count":150,"type":21},385,[75],"Cannabis use increased 10 fold among adults over the age of 65 between 2014 and 2016 but very little data exists on the extent of their harmful effects on health and behavior. The overarching goal of this project is to test a novel harm reduction strategy in which older individuals who seek to use cannabis for pain, anxiety or mood problems (depression\u002Fanxiety) will be randomly assigned to one of three conditions in an 8 week randomized controlled trial: hemp-derived CBD+THC, hemp-derived CBD-THC, or placebo. This work has the ability to directly inform individual choices regarding the use of cannabis products among older adults, and direct policy decisions regulating cannabis formulations on the legal market.",[103,154,155,156],"Anxiety","Depression","Pain",{"date":83,"type":33},{"date":159,"type":33},"2024-05-01",{"date":138,"type":21},{"name":39,"class":40},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":169,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":180,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":41},"100642878","the-ease-study-randomized-trial-of-a-novel-approach-to-addressing-fear-of-progression-in-advanced-cancer-100642878","NCT07636200","The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer","EASE","Inclusion Criteria:\n\n* Adults, age 18 or older\n* Have been diagnosed with either (a) Stage IV metastatic cancer of any solid tumor type, (b) Stage III ovarian cancer that has recurred, (c) 'extensive stage' small cell lung cancer, or (d) glioblastomas of any staging\n* Are capable at time of consent of understanding and voluntarily consenting themselves to the study, attending intervention sessions, and writing for 30 minutes, confirmed by an Eastern Cooperative Group Performance Status Scale of ≤2\n* Report elevated FoP and cancer-related trauma symptoms on the screening measures: FoP-Q 12-item short version: mean score of 2.5 (or total score of 30), IES-R: mean of 1.5 (or total score of 33)\n* Are fluent in English or Spanish and can read English proficiently (for the surveys, which are in English)\n\nExclusion Criteria:\n\n* Patients who have a history of chronic untreated trauma unrelated to their cancer, psychiatric hospitalization or suicide attempt(s) in the past 2 years, or current high suicide risk, as identified in the screening.\n* EMR-noted cognitive impairment (such as dementia) is an exclusion due to potential impairments in neural learning mechanisms that may affect the efficacy of exposure therapy.","18 Years",{"count":171,"type":21},250,[24],"Precision oncology has led to a growing population of adults with advanced cancer living increasingly longer lives in the face of profound uncertainty about the future, with over half reporting moderate to high fear of cancer progression (FoP). These fears are associated with anxiety and depression, over-use of healthcare, physical symptom burden, higher treatment regret, fatigue, and, in many studies, poorer quality of life. Moreover, FoP is strongly correlated with cancer-related trauma symptoms-physical hyperarousal, intrusiveness of cancer thoughts\u002Fimages, and avoidance of cancer-related thoughts and feelings, suggesting overlapping symptoms. While behavioral interventions exist to target fear of recurrence in early-stage cancer survivors, there is a dearth of behavioral interventions to address FoP or cancer-related trauma symptoms in adults with advanced cancer, and no known published randomized trials of such interventions in the United States. In addition, cutting-edge developments for the treatment of trauma in general populations have not been adapted to cancer populations. To address these critical gaps, we adapted a cutting-edge behavioral treatment for trauma to reduce FoP and cancer-related trauma symptoms among adults with advanced cancer. The intervention, titled EASE, is based on written exposure therapy, an efficacious approach for reducing trauma symptoms in general populations that is better accepted and far briefer than other gold-standard approaches. EASE adapts this approach to help advanced cancer patients with elevated FoP and cancer-related trauma symptoms reduce their fear of the future by using written exposure focused on their future worst-case scenario with cancer. Informed by the NIH stage model, we evaluated EASE delivered by telehealth in an open pilot trial for 29 adults with late-stage cancer and elevated FoP and cancer-related trauma symptoms. Pilot findings show strong acceptability, feasibility, and efficacy potential. We now propose to conduct the first randomized trial of EASE, and, thus, first known randomized trial in the United States of a behavioral intervention for FoP and cancer-related trauma symptoms among adults with advanced cancer. This 2-arm trial (N=250) will compare EASE delivered by telehealth with Usual Care (UC). We aim to compare EASE to UC on FoP and cancer-related trauma symptoms (primary outcomes) and anxiety, depression, hopelessness, and quality of life, at post-intervention (Aim 1) and follow-up (Aim 2). We will evaluate mechanisms for EASE relative to UC (Aim 3). Offering EASE in both English and Spanish, and by telehealth, increases access. Simple content increases scalability. Rigorous evaluation of EASE has the potential to provide a paradigm-shifting intervention ready for dissemination and to inform evidence-based care guidelines for distressed adults with advanced cancer.",[175,176,177,178,179],"Advanced Solid Tumor Cancer","Stage IV Cancer (Solid Tumors Only)","Glioblastoma","Stage III Ovarian Cancer","Small Cell Lung Cancer Extensive Stage",[181,182],"Fear of cancer progression","Cancer-related trauma symptoms","2026-06-04",{"date":106,"type":33},{"date":186,"type":33},"2026-05-04",{"date":188,"type":21},"2030-05",{"name":39,"class":40},{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":169,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":199,"phases":4,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":210,"locationsCount":62},"100639786","human-neural-correlates-of-multi-timescale-inference-100639786","NCT07606469","Human Neural Correlates of Multi-Timescale Inference","Neuronal Mechanisms of Human Cognition","Inclusion Criteria:\n\n* Epilepsy patients undergoing intracranial electrode monitoring for uncontrolled seizures.\n* no lesions identified in the participants' brains\n* capable of giving consent\n\nExclusion Criteria:\n\n* seizure activity during task recording\n* electrodes in regions of interest are identified to be the seizure focus\n* task performance outside of the normal range as determined from online studies with healthy participants",{"count":198,"type":21},30,"OBSERVATIONAL","Adult epilepsy patients who are undergoing intracranial monitoring will participate in a simple behavioral task during the clinical recording period.",[202,203],"Cognition","Brain Activity","2026-05-18",{"date":206,"type":33},"2026-05-26",{"date":30,"type":21},{"date":209,"type":21},"2028-06-30",{"name":39,"class":40},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":15,"sex":16,"minAge":169,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":228,"locationsCount":62},"100504471","studies-of-human-inference-using-on-line-testing-100504471","NCT05848752","Studies of Human Inference Using On-line Testing","Inclusion Criteria:\n\n* Adult Prolific participants who have a 95% approval rating and achieve a minimum score of 80% on our pre-test,\n* Speak fluent English\n* Are in the US.\n\nExclusion Criteria:\n\n* None",{"count":218,"type":21},500,[24],"The investigators will record behavioral responses from human participants on crowdsourcing platform Prolific to identify the decision strategies humans apply short-term, long-term, and multi timescale (across both timescales) inference tasks. Participants will perform a flexible decision-making task (described in Research Strategy Aim 1) in which subjects must determine which of two locations a series of evidence (package drops) came from. Subjects must 1) report the current location, 2) predict the next location. The investigators will record these responses, the number (and sequence) of evidence, and the response time (time from the end of trial until the response) for each trial. Subjects will perform all blocks (parameters and number of blocks to be determined by inference model development and testing prior to task development) so that we can compare responses at each timescale. Since participants participate voluntarily for small sums of money (around $12\u002F hour based on duration of task) and the investigators' previous studies have collected over 200 subjects in a matter of days, they will aim to record behavioral data from 1000 subjects. This number allows them to address the broad range of subject variability expected using Bayesian statistical methods such as Bayes factors.",[222],"Behavior","2026-05-14",{"date":204,"type":33},{"date":226,"type":33},"2025-02-15",{"date":209,"type":21},{"name":39,"class":40},{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":15,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":239,"conditions":240,"keywords":243,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":62},"100575730","adipocyte-derived-extracellular-vesicles-weight-loss-and-endothelial-function-100575730","NCT06776081","Adipocyte-Derived Extracellular Vesicles, Weight Loss, and Endothelial Function","Adipocyte-Derived Extracellular Vesicles; Novel Biomarker and Mediator of Obesity-Related Endothelial Dysfunction","Inclusion criteria:\n\n* Age ≥40 years\n* BMI \\\u003C25 kg\u002Fm2 and BMI \\>25 kg\u002Fm2 for Phase 1 and BMI \\>25 kg\u002Fm2 for Phase 2. Rationale for defining obesity as BMI \\>25 kg\u002Fm2\n\nExclusion criteria:\n\n* Current smoker\n* Chronic overt medical condition (e.g., evidence of coronary artery disease on resting ECG, any history of myocardial infarction or stroke, or cancer, diabetes based on fasting blood glucose concentration)\n* Alcohol abuse or dependence defined as more than 14 standard drinks\u002Fweek and no more than 4 standard drinks\u002Fday for men and 7 standard drinks\u002Fweek and 3 standard drinks\u002Fday for women (a standard drink is defined as 12 ounces of beer, 5 ounces of wines, 1 ½ ounces of 80-proof distilled spirits) reported during the medical history\u002Fphysical exam\n* Stage III hypertension (systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>100 mmHg)\n* Regular vigorous aerobic\u002Fendurance exercise (\\>3 bouts\u002Fweek, \\>30 minutes\u002Fbout at a workload \\>6 METS)\n* Women who are pregnant or breastfeeding\n* History of anaphylaxis to betadine, lidocaine, iodine\n* Raynaud's disease\n* History of clotting disorders\n* Anyone taking blood thinners and clotting medications\n* Anyone taking statin medication\n* Planned pregnancy in coming 4-6 months",{"count":237,"type":21},84,[24],"Changes in adipose tissue biology are now recognized as a key factor underlying the increased risk of metabolic and cardiovascular disease with obesity. Clinical interest in adipocyte-derived extracellular vesicles (Ad-EVs) has intensified due to their potential as circulating biomarkers of adipose tissue health and systemic messengers, regulators and mediators of cardiometabolic health and disease with obesity.\n\nThe investigators hypothesize that elevated Ad-EVs in adults with obesity will be negatively associated with endothelium-dependent vasodilation. Furthermore, the investigators hypothesize that in adults with obesity, intentional weight loss-induced reduction in circulating Ad-EVs is associated with greater endothelium-dependent vasodilation.",[241,242],"Obesity","Weight Loss",[241,242],"2026-04-27",{"date":246,"type":33},"2026-04-28",{"date":248,"type":33},"2024-07-01",{"date":250,"type":21},"2027-06-30",{"name":39,"class":40},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":15,"sex":258,"minAge":259,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":263,"conditions":264,"keywords":269,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":62},"100439301","inspiratory-muscle-strength-training-for-lowering-blood-pressure-and-improving-endothelial-function-in-postmenopausal-women-comparison-with-standard-of-care-aerobic-exercise-100439301","NCT05000515","Inspiratory Muscle Strength Training for Lowering Blood Pressure and Improving Endothelial Function in Postmenopausal Women: Comparison With \"Standard of Care\" Aerobic Exercise","Inclusion Criteria:\n\n* Postmenopausal women (\\>12 months of amenorrhea)\n* Estrogen deficient (no hormone therapies within the previous 12 months)\n* Age 50 years and older\n* Ability to provide informed consent\n* Willing to accept random assignment to condition\n* Resting systolic blood pressure of 120 mmHg or greater\n* Body mass index \\\u003C40 kg\u002Fm2\n* Weight stable in the prior 3 months (\\\u003C2 kg weight change) and willing to remain weight stable throughout study\n* No change in blood pressure medications or other medications (prescription or dosing) in the prior 3 months and willing to maintain current medication regimen\n* Free from clinical disease with the exception of hypertension\n\nExclusion Criteria:\n\n* Younger than age 50 years\n* Early menopause (menopause before age 45 years)\n* Having had a hysterectomy\n* History of uncontrolled hypertension (systolic blood pressure \\>180 mmHg and\u002For diastolic blood pressure \\>120 mmHg)\n* Current smoker\n* Alcohol dependence or abuse\n* Abnormal blood pressure response to exercise (drop in systolic blood pressure below resting levels or systolic blood pressure \\>260 mmHg or diastolic blood pressure \\>115 mmHg)\n* Regular vigorous aerobic\u002Fendurance exercise (\\>4 bouts\u002Fweek, \\>30 min\u002Fbout at a workload \\>6 METS)","FEMALE","50 Years",{"count":261,"type":21},90,[24],"High blood pressure (BP) is the major modifiable risk factor for cardiovascular diseases (CVD) and related health conditions, particularly among postmenopausal (PM) women. In adults age ≥50 years this risk is primarily driven by above-normal systolic BP (SBP ≥120 mmHg), as diastolic BP plateaus, then decreases in older adulthood. Although SBP is lower in premenopausal women vs. age-matched men, SBP reaches, then surpasses men after age 60. As such, \\>75% of PM women in the U.S. have above-normal SBP, which, in turn, is responsible for a 2-fold increase in risk of hypertension and corresponding increases in risk of CVD, chronic kidney disease and many other disorders. A key process linking high SBP to CVD and related conditions is vascular endothelial dysfunction, mediated by excessive reactive oxygen species (ROS)-induced oxidative stress and reductions in nitric oxide (NO) bioavailability. As the number of PM women is rapidly growing, further increases in SBP-related CV disorders are projected without effective intervention.\n\n* Aerobic exercise (AE) is a first-line, standard-of-care therapy for lowering BP. In PM women with baseline SBP ≥120 mmHg, AE reduces casual (resting) SBP by \\~3 mmHg (back to baseline ≤4 weeks post-training), whereas 24-hour SBP is typically unchanged. However, only 25-30% of PM women meet guidelines for 150 min\u002Fweek of moderate-intensity AE, citing the extensive time requirement, facility access and travel disruptions as major barriers. Another, far less recognized, limitation is that AE training consistently improves endothelial function in midlife\u002Folder men, but not in estrogen-deficient PM (PMe-) women, i.e., in \\>95% of the 60+million PM women in the U.S. Thus, establishing new lifestyle therapies that induce and sustain reductions in SBP and increases in endothelial function in PMe- women with above-normal SBP is an important public health goal.\n* High-resistance inspiratory muscle strength training (IMST) is a time-efficient (5 minutes per session) lifestyle intervention consisting of 30 inspiratory maneuvers performed against a high resistance. Preliminary data suggest 6-weeks of IMST performed 6 days\u002Fweek reduces SBP by 9 mmHg in adults with above-normal SBP (i.e., greater than 120 mmHg) at baseline. Importantly, this reduction in SBP is equal to or greater than the reduction in blood pressure typically achieved with time- and effort-intensive healthy lifestyle strategies like conventional aerobic exercise. In addition, IMST improved endothelial function in the PMe- women in a small pilot study.\n* To translate these promising preliminary results towards clinical practice, this randomized clinical trial is being conducted to directly compare the efficacy of a longer, clinically relevant treatment duration of IMST (3 months) against home-based, moderate-intensity (standard-of-care) AE in PMe-women. The primary outcome will be the change in casual SBP (IMST vs. AE). Changes in 24-hour SBP and endothelial function will serve as secondary outcomes. Effects on NO bioavailability, ROS\u002Foxidative stress, and the role of \"circulating factors\" will provide insight into mechanisms of action. The sustained effects on SBP and endothelial function also will be assessed.\n* Accordingly, a randomized, blinded, sham-controlled, parallel group design clinical trial will be conducted to assess the efficacy of 3-months of IMST (75 percent maximal inspiratory pressure) vs. brisk walking (40-60% heart rate reserve; an established healthy lifestyle strategy) for lowering SBP and improving endothelial function in PMe- women age 50 years and older with above-normal SBP. It is hypothesized that IMST will lower SBP and improve endothelial function by decreasing oxidative stress and increasing nitric oxide bioavailability. It is also expect that adherence to the intervention will be excellent (over 80 percent of all training sessions completed at the appropriate intensity).\n* To test this hypothesis, 90 PMe- women age 50 years and older who have SBP \\>\u002F= 120 mmHg will be recruited. Participants will undergo baseline testing for casual (resting) SBP, 24-hour ambulatory SBP and endothelial function. Innovative mechanistic probes including pharmaco-dissection with vitamin C, analysis of biopsied endothelial cells, and high-throughput metabolomics, will be performed to assess oxidative stress and nitric oxide bioavailability at baseline.\n* After baseline testing, subjects will be randomized to perform either 3-months of high-resistance IMST or brisk walking. Subjects will train 6 days\u002Fweek. Following 3 months of training, subjects will redo all the tests that were done during baseline testing to assess training-induced changes in SBP, physiological functions, and underlying mechanisms. Subjects will then cease training for 6 weeks before returning to the lab for follow-up testing to determine the persistent effects of IMST.",[265,266,267,268],"Aging","Blood Pressure","Endothelial Dysfunction","Hypertension",[270,271],"Above-normal blood pressure","Inspiratory muscle strength training","2026-01-12",{"date":274,"type":33},"2026-01-14",{"date":276,"type":33},"2022-04-19",{"date":278,"type":21},"2027-02-28",{"name":39,"class":40},{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":16,"minAge":288,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":22,"phases":291,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":300,"locationsCount":62},"100536575","phase-2-cannabis-for-palliative-care-in-cancer-100536575","NCT06266611","Cannabis for Palliative Care in Cancer","Cannabis for Palliative Care in Cancer: A Placebo-controlled Randomized Trial of Full Spectrum Hemp-derived CBD\u002FTHC","ARCTiC","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. Aged ≥25 years at Visit 1 (Baseline)\n3. Have a diagnosis of any solid tumor type and is currently undergoing or has undergone either curative or palliative treatment in the past 18 months\n4. Currently experiencing symptoms of sleep problems, pain, and\u002For mood disturbance (i.e., depression, anxiety)\n5. Desire to use cannabis to treat their symptoms\n6. Must not have been regularly using any cannabis products (more than 3x\u002Fmonth) in the last 6 months\n7. Willing to practice acceptable methods of birth control until completing study medication\n\nExclusion Criteria:\n\n1. Report of illegal drug use (e.g., cocaine, methamphetamine) in the past 90 days\n2. Current use of anti-epileptic medications (e.g., clobazam, sodium valproate, lamotrigine)\n3. Current use of medications known to have major interactions with Epidiolex (e.g., buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, teriflunomide)\n4. Current use of anti-psychotic medications\n5. Current use of potent CYP2C19 or CYP3A4 inducers (e.g., Rifampin, apalutamide, carbamazepine, enzalutamide, ivosidenib9, lumacaftor, ivacaftor, phenytoin, St. John's wort, Fosphenytoin, Mitotane, Phenobarbital, Primidone)\n6. Liver function tests (Alanine transaminase \\[ALT\\] and Aspartate transaminase \\[AST\\]) levels ≥2x the upper normal limits\n7. Moderate or severe liver disease\n8. Past or current diagnosis, or family history of diagnosis, of psychosis; current major psychiatric illness, such as bipolar disorder, major depression, or schizophrenia\n9. History of seizures\n10. For female participant of childbearing potential: Pregnant or lactating at the time of study enrollment or trying to become pregnant. Lack of childbearing potential confirmed by a history of amenorrhea for at least 12 consecutive months and serum FSH level within the laboratory's reference range for postmenopausal females OR documented bilateral oophorectomy and\u002For hysterectomy\n11. Physician response to passive consent indicating contraindications for participation.\n12. Unwilling to refrain from cannabis use other than study drug for the entire study duration\n13. Men who consume more than 2 alcoholic beverages per day and women who consume more than 1 alcoholic beverage per day","25 Years",{"count":290,"type":21},185,[75],"Many cancer patients suffer from pain, sleep, and mood problems and are using cannabis to relieve these symptoms. Cannabis may provide such relief but may also produce negative side effects including cognitive impairment, an especially problematic issue for cancer patients, indicating more research on cannabis use in the cancer context is required. In this endeavor, the present study seeks to compare the use of hemp-derived CBD (Cannabidiol) with and without THC (Delta-9-tetrahydrocannabinol) versus placebo on measures of sleep, pain, mood, subjective and objective cognitive functioning, and quality of life within 185 cancer patients.",[103,154,155,156],"2025-07-29",{"date":296,"type":33},"2025-08-01",{"date":298,"type":33},"2024-09-16",{"date":209,"type":21},{"name":39,"class":40},{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":15,"sex":16,"minAge":71,"maxAge":123,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":62},"100561316","perceptual-influences-from-smoking-cannabis-an-experimental-study-100561316","NCT06588582","Perceptual Influences From Smoking Cannabis: an Experimental Study","Exploring the Antecedents and Consequences of Cannabis Use in the Context of Coping: An Experimental Study","PISCES","Inclusion Criteria:\n\n* 21-65 years of age\n* Endorsement of at least some use of cannabis for coping purposes (\\>1 on CMMQ)\n* Regularly use flower cannabis products (i.e., ≥1x\u002Fweek in the last 6 months)\n* Proficient in English language\n* At least occasional use of CBD+THC or CBD-dominant products (e.g., ≥1x\u002Fmonth)\n\nExclusion Criteria:\n\n* Diagnosis or use of medications for substance use or psychotic disorders\n* Report of other drug use (cocaine, opiates, methamphetamine) in the past 90 days or fail urine screen for any of these drugs\n* Females cannot be pregnant or trying to become pregnant or nursing mothers\n* Not able to provide informed consent",{"count":310,"type":21},166,[24],"The purpose of the study is to better understand the effects of cannabis in relation to mental and physical states including its relationship with mood, cognition, perception including the experience of temperature and pain, and heart rate.\n\nWe expect that participants will be in this research study for approximately one week. The total amount of time that participants will spend completing study tasks will be about 2.5 hours across two separate in-person visits.",[314,315],"Cannabis Use","Stress","2025-06-12",{"date":318,"type":33},"2025-06-13",{"date":320,"type":33},"2025-02-17",{"date":322,"type":21},"2029-07-31",{"name":39,"class":40},{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":15,"sex":16,"minAge":330,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":22,"phases":334,"briefSummary":335,"conditions":336,"keywords":338,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":62},"100593801","neural-substrates-underlying-adaptations-in-manual-dexterity-of-older-adults-100593801","NCT07011160","Neural Substrates Underlying Adaptations in Manual Dexterity of Older Adults","Inclusion Criteria:\n\nCommunity-dwelling men and women who are 54-89 years of age and able to give fully informed consent; able to read, write, and speak English to ensure safe participation in the project; and able to arrange own transportation to Boulder campus.\n\nExclusion Criteria:\n\nCognitive impairment, major psychiatric condition, or unstable depressive disorder that would influence the ability to understand the study and cooperate fully in the proposed protocols; any progressive neurological, muscular, cardiovascular, or skeletal disorder that limits participation, such as (but not limited to) (1) amyotrophic lateral sclerosis, multiple sclerosis, multiple system atrophy, muscular dystrophy, myasthenia gravis, Parkinson's disease, spinal muscular atrophy, spinocerebellar ataxia, or spasticity; (2) congenital, mitochondrial, or thyrotoxic myopathies, fibromyalgia, or myositis; (3) peripheral neuropathy, diabetes, or hypertension; or (4) cancer, gout, osteoarthritis with severe pain, or rheumatoid arthritis; chronic pain condition that would impair the ability to participate in the study; currently taking prescribed medication known to influence neuromuscular function, such as carisoprodol, cyclobenzaprine, metaxalone, and methocarbamol; function-limiting injury to the hands, arms, shoulders, neck, or legs; recent hospitalization (within the last 3 months) or enforced bedrest\u002Fsedentary state; inability to attend the evaluation and practice sessions in 2 weeks.","54 Years","89 Years",{"count":333,"type":21},72,[24],"Age-related declines in motor function can compromise independence and quality of life. This project examines how practice and somatosensory stimulation reshape the neural control of hand muscles in older adults, leveraging neuroplasticity to enhance dexterity. By identifying modifiable neural mechanisms that underlie improved motor performance, this research lays the groundwork for targeted, non-invasive interventions that can be translated into clinical and community settings to support healthy aging and functional independence.",[337],"Aging Hands",[339,340,341,342],"manual dexterity","force steadiness","motor units","neuroplasticity","2025-05-30",{"date":345,"type":33},"2025-06-08",{"date":347,"type":21},"2026-04-01",{"date":349,"type":21},"2030-03-30",{"name":39,"class":40},{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":16,"minAge":169,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":22,"phases":362,"briefSummary":363,"conditions":364,"keywords":369,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":62},"100567839","group-exposure-workshops-for-socially-anxious-undergraduates-100567839","NCT06673407","Group Exposure Workshops for Socially Anxious Undergraduates","Pilot Trial on the Contribution of Peer Leaders and Self-Compassion to Group Exposure Workshops for Socially Anxious Undergraduates","OASIS","Inclusion Criteria:\n\n* Age = 18-30\n* Able to read and write fluently in English\n* Current undergraduate students at CU\n* Experiencing elevated social anxiety symptoms indicated by a SPIN score ≥ 19\n* Experiencing moderate to high communication anxiety indicated by a PRCA- 24 score ≥ 59\n* Open to receiving help for social anxiety or public speaking fears indicated by a help seeking score of ≥ 3 out of 5 (at both screening timepoints as explained below)\n* Able to voluntarily consent to participation\n* Able to participate fully in the study (including in the in-person group workshops and in survey completion) as assessed by screening questions and the study P\n\nExclusion Criteria:\n\n* Are currently experiencing moderately severe or severe depression represented by the validated cutoff score for major depression on the PHQ-8 of greater than 14 (Kroenke et al., 2001)\n* Score in the moderate-high range for suicide risk as indicated by the CSSRS (Salvi, 2019), report a suicide attempt in the past 12 months, or report current, ongoing suicidal ideation along with a past (lifetime) suicide attempt\n* Are current students of the PI or clients or current students of the doctoral student co-facilitators","30 Years",{"count":361,"type":21},200,[24],"The purpose of the study is to investigate the effects of four versions of a workshop for social anxiety and public speaking stress. All participants are current University of Colorado Boulder undergraduate students. Participation in this research study lasts for approximately 8 weeks, and includes a pre-workshop questionnaire, 3 weekly workshop sessions (ranging from 2 to 3 hours each, including a 5-minute post-session questionnaire), a post-workshop questionnaire, and a 1-month follow-up questionnaire.",[365,366,367,368],"Social Anxiety Disorder","Public Speaking Fear","Public Speaking Anxiety","Social Fear",[370,367,371,372,373,374],"Social Anxiety","Exposure Therapy","Peer-led","Self-compassion","Common Humanity","2025-05-15",{"date":377,"type":33},"2025-05-20",{"date":379,"type":33},"2024-06-12",{"date":381,"type":21},"2025-10-01",{"name":39,"class":40},{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":15,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":22,"phases":391,"briefSummary":392,"conditions":393,"keywords":394,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":62},"100462385","passive-heat-therapy-for-lowering-systolic-blood-pressure-and-improving-vascular-function-in-mid-life-and-older-adults-100462385","NCT05300971","Passive Heat Therapy for Lowering Systolic Blood Pressure and Improving Vascular Function in Mid-life and Older Adults","Inclusion Criteria:\n\n* Able to provide informed consent (no clinical diagnosis of dementia or related diseases AND mini mental state exam score \\>20).\n* Willing to accept random assignment to intervention.\n* Aged 40+ years.\n* Premenopausal women must not be pregnant (confirmed by urine pregnancy test).\n* Casual systolic blood pressure 115-159 mmHg.\n* Sufficiently healthy to undergo heat stress, as determined by the CTRC physician Dr. Wolfe and physician of record Dr. Chonchol based on medical history, physical exam, blood chemistries, and 12-lead ECG at rest and during the graded exercise test. Subjects with established clinical diseases may participate so long it is not determined that heat therapy could be detrimental to their health (determined case-by-case, but examples of subjects who may be excluded include those currently undergoing chemotherapy treatment or chronic kidney disease patients requiring dialysis).\n* Ability to refrain from the use of dietary supplements, anti-inflammatory medications, and prescription medications prior to experimental testing and\u002For water immersion visits in some cases (occasionally used PDE5 inhibitors and nitrites) (for the durations described above), as determined by the CTRC physician and approved by the subject's primary care provider if deemed necessary (see Procedures below for more detail). (rationale: many of these agents can acutely modulate vascular function).\n* Weight stable in the prior 3 months (≤ 2 kg weight change) and willing to remain weight stable over the course of the study.\n* Willing to maintain physical activity, diet, and other lifestyle factors for the entire 6-month duration of the study.\n* Free from alcohol dependence or abuse, as defined by the American Psychiatry Association, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).\n\nExclusion Criteria:\n\n* Individuals taking 3+ anti-hypertensive medications (rationale: these individuals typically have resistant or secondary hypertension. Individuals taking 1-2 anti-hypertensive medications will still be included, with the exception of beta-blockers.)\n* SBP 140-159 mmHg but not on anti-hypertensive medications. (rationale: ACC\u002FAHA guidelines indicate that immediate pharmacotherapy is advised for these individuals. Potential subjects with SBP in this range will discuss options\u002Freceive recommendations from a CTRC physician and be referred to their primary care provider. If they begin anti-hypertensive medication, they will be eligible to participate in the study after they have been on them for at least 3 months, assuming they still qualify. If they decide not to begin anti-hypertensive medications, they must receive approval for their primary care provider that it is ok for them to participate in the study.)\n* Regular vigorous aerobic\u002Fendurance exercise: \\>4 bouts per week for \\>30 min per bout at a workload of \\>10 METS, determined based on screening surveys and workload confirmed by MAQ during Visit 1. (rationale: aerobic exercise training independently lowers blood pressure and improves arterial function33,74,75).\n* Body mass index (BMI) \\>40 kg\u002Fm2 (rationale: BP and vascular measurements can be inaccurate in severely obese subjects and these subjects may differ in many ways from normal weight, overweight, or less obese subjects).\n* Current use of anticholinergics (e.g. amitriptyline), alpha-blockers (e.g. Flomax), and beta-blockers (e.g., propranolol) (rationale: these medications can interfere with thermoregulation and\u002For control of blood pressure during heat stress). \\*Note: anti-hypertensive medications besides beta-blockers will be allowed-see \"Additional considerations for subjects taking anti-hypertensive medications\" below under the intervention procedures for Section XI.).\n* Current use of certain prescription medications taken at a dose or frequency high enough to potentially interfere with thermoregulation and\u002For blood pressure control during heat stress. These include nitrates and nitrites (e.g. nitroglycerin), PDE5 inhibitors (e.g. Viagra), amphetamines (e.g., ADD\u002FADHD drugs), insulin, and thyroid medications. Risk of each of these classes of medications depends on dose and other medications also being taken. Thus, Drs. Wolfe and Chonchol will make decisions whether subjects taking these medications should be excluded. (Note: occasional use of PDE5 inhibitors and nitrates ok so long as they are not taken for the following durations around water immersion sessions, PDE5 inhibitors: 24 hours before through the 8 hours after; nitrates: 8 hours before through 8 hours after, and (for both classes of medications) in the 48 hours before through the 48 hours after visits in which nitroglycerin is administered \\[visits 3, 10, \\& 13\\] - Drs. Wolfe and Chonchol can extend these durations as they deem necessary and will have the opportunity to do so during the medication review process at screening).\n* Orthostatic hypotension, as determined by medical history or during screening as a reduction of \\>20 mmHg on SBP and\u002For \\>10 mmHg in diastolic BP within 3 min of going from seated to standing (rationale: passive heat therapy is contraindicated for individuals with orthostatic hypotension).\n* Active, untreated atrial fibrillation or flutter (rationale: it is possible individuals with atrial fibrillation\u002Fflutter may have a higher risk of arrhythmias during hot water immersion).\n* Unstable cardiovascular diseases (e.g., unstable angina or recent myocardial infarction or stroke) (rationale: heat therapy is contraindicated for individuals with unstable CVDs).\n* Recent major change in health status within previous 3 months (e.g., surgery, significant infection or illness, including COVID-19). What is considered \"major\" or \"significant\" may be evaluated by the physician of record on a case-by-case basis. An example of a surgery that would likely not be considered \"major\" is out-patient removal of a basal cell carcinoma. \"Significant\" infections include those requiring hospitalization or long durations (i.e., months) of recovery. Additionally, subjects with acute fever\u002Fillness (Tre ≥ 38.0°C) will not be able to undergo screening or participate in water immersion sessions until fever\u002Fillness has resolved. Subjects with a confirmed positive case of COVID-19 will not be able to participate until COVID-19 symptoms have resolved and 2 weeks after diagnosis. Subjects will be asked to let us know if they are sick so that sessions\u002Ftesting can be rescheduled.\n* Open wounds or skin lesions. History of skin-related conditions or sensitivities to prolonged water immersion or exposure to pool chemicals.\n* Blood donation within the past 2 months (if subjects have donated blood within the last 2 months, we will ask if they are willing to delay the start of the study until it has been 2 months since their last blood donation)\n* Inability to tolerate blood draws, intravenous catheters, including past fainting in response to blood sampling. (rationale: at the least, we must be able to obtain enough blood for clinical chemistries to ensure safety).",{"count":390,"type":21},150,[24],"This study aims to determine the effects of \\~12 weeks of repeated hot water immersion (\"heat therapy\") vs. thermoneutral water immersion on blood pressure and vascular function in late middle-life to older (≥40 years) adults. The study also aims to determine the effects of \\~12 weeks of heat therapy on fluid cognitive and cerebrovascular function.",[265],[395,396,397,398,399],"Endothelial function","Arterial stiffness","Heat","Hot water immersion","Systolic blood pressure","2025-04-23",{"date":402,"type":33},"2025-04-29",{"date":404,"type":33},"2022-08-01",{"date":406,"type":21},"2028-02-01",{"name":39,"class":40},{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":16,"minAge":169,"maxAge":123,"enrollmentInfo":415,"targetDuration":4,"studyType":22,"phases":417,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":62},"100477745","reducing-fatigue-in-people-with-multiple-sclerosis-by-treatment-with-tens-100477745","NCT05500963","Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS","Reducing Fatigue in People With Multiple Sclerosis by Treatment With Transcutaneous Electrical Nerve Stimulation","Inclusion Criteria:\n\n* Men and women18-65 yrs\n* Able to read, understand, and speak English to ensure safe participation in the project\n* Clinical diagnosis of relapsing-remitting MS\n* Self-reported difficulty with walking\n* On stable doses of Ampyra, provigil, or other symptomatic-treating medications\n* No relapse or systemic steroids within the last 30 days\n* Able to arrange transportation to the Boulder campus\n\nExclusion Criteria:\n\n* Vision or hearing problems that have not been corrected\n* Problems with sensations to temperature, pressure, or pain\n* Any arm or leg problems that would influence the ability to hold a weight\n* Surgery to the arms or legs that continues to bother the participant\n* Metal implants\n* Medical diagnosis or condition that is considered to be an absolute or relative contraindication to participating in exercise training, such as major renal, pulmonary, hepatic, cardiac, gastrointestinal, HIV, cancer (other than treated basal cell cancer), other neurological disorders, or pregnancy\n* History of head injury or stroke\n* Taking antidepressants, anticholinergics, stimulants, sedatives, cannabis, illicit drugs or medications to treat herpes or neurologic pain.\n* Diagnosis of diabetes mellitus\n* Poorly controlled hypertension\n* History of seizure disorders\n* ≥2 alcoholic drinks\u002Fday, or present history (last 6 months) of drug abuse\n* Spasticity that requires the individual to change intended activities more often than once a week\n* Skin diseases or sensation problems in the legs or hands that influences some activities more often than once a week\n* Inability to attend exercise sessions 3 days per week for 6 weeks",{"count":416,"type":21},60,[24],"The objective of the randomized, sham-controlled trial will be to evaluate the effectiveness of treatment with transcutaneous electrical nerve stimulation (TENS) at reducing the level of fatigue experienced by people with MS.",[420],"Multiple Sclerosis","2024-12-05",{"date":423,"type":33},"2024-12-09",{"date":425,"type":33},"2023-04-25",{"date":427,"type":21},"2028-11-30",{"name":39,"class":40},""]